US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BioCorRx Inc.

0.2600

0.0000

Volume:- -

Turnover:- -

Market Cap:6.37M

PE:-0.80

High:0.2600

Open:0.2600

Low:0.2600

Close:0.2600

52wk High:0.5000

52wk Low:0.1995

Shares:24.49M

Float Shares:8.60M

Volume Ratio:1.96

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.3253

EPS(LYR):-0.4880

ROE:145.76%

ROA:-82.89%

PB:-0.47

PE(LYR):-0.53

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

BioCorRx Inc. CEO to Present Live at Life Sciences Virtual Investor Forum

BioCorRx Inc. reports Q3 revenue of $635,224 and reduced net loss

BioCorRx Inc. Enters Securities Purchase Agreement for $350,000, Issuing 1,000,000 Shares and Warrants to Accredited Investors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BICX"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BICX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BICX\",,,,,undefined,":{"symbol":"BICX","market":"US","secType":"STK","nameCN":"BioCorRx Inc.","latestPrice":0.26,"timestamp":1770411600000,"preClose":0.26,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":8599900,"shares":24489311,"eps":-0.325266,"marketStatus":"Market Closed","change":0,"latestTime":"02-06 16:00:00 EST Delay","open":0.26,"high":0.26,"low":0.26,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.325266,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"PINK","adjPreClose":0.26,"volumeRatio":1.9604050017849326},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BICX\",,,,,undefined,":{"symbol":"BICX","floatShares":8599900,"roa":"-82.89%","roe":"145.76%","lyrEps":-0.487953,"volumeRatio":1.9604050017849326,"shares":24489311,"dividePrice":0,"high":0.26,"amplitude":0,"preClose":0.26,"low":0.26,"week52Low":0.1995,"pbRate":"-0.47","psRate":"6.71","week52High":0.5,"institutionHeld":0,"latestPrice":0.26,"eps":-0.325266,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.325266,"open":0.26,"prevYearClose":0.2911,"prevWeekClose":0.3,"prevMonthClose":0.3,"prevQuarterClose":0.2911,"fiveDayClose":0.3,"twentyDayClose":0.3176,"sixtyDayClose":0.46},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BICX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-14","symbol":"BICX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-08-13","symbol":"BICX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-05-15","symbol":"BICX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-04-01","symbol":"BICX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1711944000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-08-14","symbol":"BICX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1691985600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BICX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BICX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BICX\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2590580836","title":"BioCorRx Inc. CEO to Present Live at Life Sciences Virtual Investor Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2590580836","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590580836?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:35","pubTimestamp":1765373710,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCorRx Inc. published the original content used to generate this news brief via GlobeNewswire  on December 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL9Fr2Jw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","SG9999014021.USD","IE00BGHQF748.EUR","BK4185","NDAQ","SG9999014039.USD","BK4585","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014005.SGD","BICX","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU0314104364.USD","SG9999014013.SGD","BK4588","LU2210149790.SGD"],"gpt_icon":0},{"id":"2584953929","title":"BioCorRx Inc. reports Q3 revenue of $635,224 and reduced net loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2584953929","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584953929?lang=en_us&edition=fundamental","pubTime":"2025-11-18 22:14","pubTimestamp":1763475256,"startTime":"0","endTime":"0","summary":"BioCorRx Inc. reported revenue of $635.2 thousand for the third quarter of 2025, compared to $0 in the same period of 2024, primarily due to sales and distribution of LUCEMYRA through its subsidiary BioCorRx Pharmaceuticals Inc. Revenue for the nine months ended September 30, 2025, rose to $948.4 thousand from $7.7 thousand in the prior-year period. The company reduced its net loss to $808.5 thousand in Q3 2025 from $1.5 million in Q3 2024. During the quarter, BioCorRx continued integrating the LUCEMYRA acquisition and advanced development of BICX104 for opioid and alcohol use disorders. Management anticipates continued revenue consistency as commercial distribution expands.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCorRx Inc. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL9zk6n9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4185","BICX"],"gpt_icon":0},{"id":"2556845193","title":"BioCorRx Inc. Enters Securities Purchase Agreement for $350,000, Issuing 1,000,000 Shares and Warrants to Accredited Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2556845193","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556845193?lang=en_us&edition=fundamental","pubTime":"2025-08-02 04:16","pubTimestamp":1754079369,"startTime":"0","endTime":"0","summary":"BioCorRx Inc. Enters Securities Purchase Agreement for $350,000, Issuing 1,000,000 Shares and Warrants to Accredited Investors. BioCorRx Inc., a Nevada corporation, entered into a securities purchase agreement on July 29, 2025, with accredited investors. The transaction involved the purchase of 1,000,000 shares of common stock and a warrant to purchase up to an additional 1,000,000 shares, for a total aggregate purchase price of $350,000. The warrant is exercisable at a price of $0.35 per share and is valid for five years from the date of issuance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCorRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nNDL9Fz3fp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4185","BICX"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BICX\",params:#limit:6,delay:false,,,undefined,":[]}}